MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Cuts Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 1.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 59,887 shares of the company's stock after selling 852 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.07% of IDEXX Laboratories worth $24,760,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in IDXX. Norges Bank purchased a new stake in shares of IDEXX Laboratories during the 4th quarter valued at about $412,258,000. Flossbach Von Storch SE increased its stake in IDEXX Laboratories by 5,439.3% during the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock worth $195,696,000 after acquiring an additional 464,791 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in IDEXX Laboratories during the fourth quarter valued at approximately $156,412,000. William Blair Investment Management LLC raised its position in IDEXX Laboratories by 701.6% during the fourth quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock valued at $174,527,000 after purchasing an additional 369,471 shares during the period. Finally, Assenagon Asset Management S.A. lifted its stake in shares of IDEXX Laboratories by 265.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock valued at $179,867,000 after purchasing an additional 316,048 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Up 1.2%

Shares of NASDAQ:IDXX traded up $6.11 on Friday, hitting $518.10. 524,927 shares of the company's stock were exchanged, compared to its average volume of 649,734. The stock has a market capitalization of $41.67 billion, a price-to-earnings ratio of 48.56, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $545.43. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The business's 50 day simple moving average is $431.28 and its two-hundred day simple moving average is $431.28.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. The company had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter last year, the business posted $2.71 EPS. Analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Bank of America boosted their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. StockNews.com raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. Piper Sandler lifted their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Finally, Morgan Stanley upped their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of "Moderate Buy" and an average target price of $524.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.